肝纖維化治療市場：依療法、疾病、通路和地區分類

Liver Fibrosis Treatment Market, By Treatment Type, By Condition, By Distribution Channel, By Geography

出版日期: 2026年07月20日 | 出版商:

Coherent Market Insights | 英文 257 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，肝纖維化治療市場在2026年將達到226億美元，預計2033年將達到470億美元。預計從2026年到2033年，該市場將以11%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	226億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.00%	2033年市場規模預測：	470億美元

肝纖維化是指細胞外基質蛋白（包括膠原蛋白）過度積聚，常見於大多數類型的慢性肝病。晚期肝纖維化可導致肝硬化、肝功能衰竭和門靜脈高壓，通常需要進行肝臟移植。肝纖維化的特徵是肝臟反覆或持續受損，導致肝內形成異常數量的疤痕組織。纖維化本身通常無症狀，但嚴重的疤痕形成可導致肝硬化及其他症狀。為了確定慢性肝病的嚴重程度，醫護人員會進行血液檢查、影像檢查，並視需要進行肝臟切片檢查。肝纖維化的治療重點在於治療其根本病因。這通常可以預防或延緩肝臟纖維化的進一步發展，從而改善病情。肝纖維化的主要治療方法包括使用抗病毒藥物、清除或溶解膽管阻塞、改變生活方式（例如減少酒精攝取）、控制肥胖和超重，以及控制非酒精性脂肪肝患者的血糖值和血脂水平。

市場動態

隨著高脂飲食消費人群的增加，非酒精性脂肪性肝炎 (NASH) 的盛行率預計在預測期內將上升。肥胖、糖尿病、肝纖維化和 NASH 的增加預計將推動市場成長，各大公司正致力於開發這些疾病的治療方法。例如，根據美國國家生物技術資訊中心 (NCBI) 2022 年 4 月的數據，過去十年間，美國 NASH 的盛行率顯著上升。這被認為與人們對該疾病的認知提高以及風險因素的盛行率上升有關。 2021 年，NASH 患者的性別組成中，女性佔 54.1%，男性佔 45.9%。專家估計，美國約有 24% 的成年人患有非酒精性脂肪肝病 (NAFLD)，約有 1.5% 至 6.5% 的成年人患有 NASH。非酒精性脂肪肝病（NAFLD）是一種單純性脂肪肝，其中20%至30%的患者會發展為非酒精性脂肪性肝炎（NASH）。另有20%至30%的患者會發展為較晚期的NASH纖維化，最終階段為NASH肝硬化。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數介紹了全球肝纖維化治療市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
這份「全球肝纖維化治療市場」報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等行業相關人員相關者。
相關人員可以透過利用分析全球肝纖維化治療市場中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第8章競爭情勢

熱圖分析
市佔率分析
公司簡介
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Johnson and Johnson
- Novartis AG
- Vertex Pharmaceuticals Incorporated
- Pfizer Inc.
- FibroGen, Inc.
- Pharmaxis Limited
分析師意見

第9章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2320

Liver Fibrosis Treatment Market is estimated to be valued at USD 22.6 Bn in 2026 and is expected to reach USD 47 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 22.6 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.00%	2033 Value Projection:	USD 47 Bn

Liver fibrosis is the excessive accumulation of extracellular matrix proteins including collagen that occurs in most types of chronic liver diseases. Advanced liver fibrosis results in cirrhosis, liver failure, and portal hypertension and often requires liver transplantation. Liver fibrosis is characterized by repeated or continuous damage to liver resulting in an abnormally large amount of scar tissue in the liver. Fibrosis does not show any symptoms, however severe scarring results into cirrhosis, which further leads to cause symptoms. To detect the severity of chronic liver disease, healthcare professionals conduct blood and imaging test, followed by liver biopsy, if required. In the possible treatment options for liver fibrosis, healthcare professionals focus on treating the cause, which often stops and slows down further scarring of liver and results in improvement of the condition. The possible treatment options for liver fibrosis include use of antiviral drugs, removal or dissolution of a blockage in the bile ducts, lifestyle changes such as lower consumption of alcohol, control regime for obesity and overweight, and controlling blood sugar & lipid levels in people with nonalcoholic fatty liver.

Market Dynamics

The underlining prevalence cases of Non-alcoholic Steatohepatitis (NASH) are expected to increase over the forecast period with increasing amount of population consuming high fat diet. Increasing obesity and diabetes epidemics, liver fibrosis, and NASH are expected to drive market growth, as key players are focused on developing treatment for these disorders. For instance, in April 2022, according to National Center for Biotechnology Information, the prevalence of NASH has significantly increased in the U.S. in the last decade. This is likely related to the increased prevalence of risk factors as well as increased awareness of the disease. The proportion of patients with NASH by gender was 54.1% female verses 45.9% male in 2021. Experts estimate about 24% of U.S. adults have Non-alcoholic fatty liver disease (NAFLD) and about 1.5% to 6.5% of U.S. adults have NASH. Non-alcoholic fatty liver disease (NAFLD) states as simple fat, which impacts on 20% to 30% of those individuals who progress to nonalcoholic steatohepatitis (NASH). Another 20% to 30% of individual's progress to more advanced Non-alcoholic Steatohepatitis (NASH) fibrosis, and the final stage is Non-alcoholic Steatohepatitis (NASH) cirrhosis.

Key features of the study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global liver fibrosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Gilead Sciences, Inc., Merck & Co., Inc., Bristol-Myers Squibb, Johnson and Johnson, Novartis AG, Vertex Pharmaceuticals Incorporated, Pfizer Inc., FibroGen, Inc., and Pharmaxis Limited
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global liver fibrosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global liver fibrosis treatment market

Market Segmentation

By Treatment Type (Revenue, USD Bn, 2021-2033)
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
ACE Inhibitors
Hepatotropic Drug
Others
By Condition (Revenue, USD Bn, 2021-2033)
Chronic Liver Diseases
Hepatitis C
Nonalcoholic Steatohepatitis
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospitals
Specialty Clinics
Others
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players
Gilead Sciences, Inc.
Merck & Co., Inc.
Bristol-Myers Squibb
Johnson and Johnson
Novartis AG
Vertex Pharmaceuticals Incorporated
Pfizer Inc.
FibroGen, Inc.
Pharmaxis Limited

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Treatment Type
- Market Snapshot, By Condition
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Disease Type Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Liver Fibrosis Treatment Market, By Treatment Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Peroxisome Proliferator-activated Receptors (PPAR)-alpha agonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Hepatotropic Drug
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Liver Fibrosis Treatment Market, By Condition, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Chronic Liver Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Hepatitis C
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Nonalcoholic Steatohepatitis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Liver Fibrosis Treatment Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Liver Fibrosis Treatment Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Condition, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Gilead Sciences, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Merck & Co., Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Bristol-Myers Squibb
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Johnson and Johnson
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Vertex Pharmaceuticals Incorporated
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- FibroGen, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pharmaxis Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views